- Pfizer's (PFE) Xalkori (Crizotinib) treatment met the main goal of a Phase III trial of untreated patients with a certain form of lung cancer by "significantly prolonging progression-free survival (PFS)" when compared with standard chemotherapy.
- The study, called Profile 1014, is the second positive global Phase III test that evaluated Xalkori against chemotherapy.
- Xalkori has already been authorized to treat previously treated patients. (PR)
From other sites
at MarketRealist.com (Fri, 4:01PM)
at 4-traders.com (Tue, 11:56AM)
at Zacks.com (Tue, 10:50AM)
at Zacks.com (Mon, 4:47PM)
at Nasdaq.com (Mar 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs